Sanofi India Limited reported a net profit of ₹835 million for the quarter ended June 30, 2026, reflecting a 20.1% year-on-year increase from ₹695 million in the corresponding period of FY25. The pharmaceutical company’s total income from operations rose 7% to ₹4,439 million, up from ₹4,150 million in Q1FY25, indicating resilient demand despite broader market headwinds. This performance underscores the firm's ability to maintain profitability through operational discipline and strategic pricing.

The Board of Directors approved the unaudited financial results at a meeting held on August 4, 2026, in Mumbai. The figures have been reviewed by the Audit Committee and prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. The results were published in Business Standard (English) and Sakal (Marathi) on August 5, 2026, pursuant to Regulations 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Highlights

For the half-year period ended June 30, 2026, Sanofi India recorded a net profit after tax of ₹1,861 million, compared to ₹1,890 million in the same period last year. Total income for the half-year was ₹9,206 million, slightly down from ₹9,542 million in H1FY25. The company’s equity share capital remained unchanged at ₹230 million.

What the Numbers Show

While revenue growth moderated in the half-year view, the quarter-on-quarter improvement in net profit highlights effective cost management. The net profit before tax increased by 19.3% year-on-year to ₹1,123 million in Q1FY27, outpacing the 7% revenue growth. This divergence suggests an expansion in operating margins or favorable one-time adjustments, although the filing does not disclose specific exceptional items for the current quarter. The consistency in equity share capital indicates no new dilutive issuances during the period.

Sanofi India Limited reported a robust second quarter of fiscal year 2026 (Q2FY26), with profit before tax rising 19% year-on-year to ₹1,123 million. The pharmaceutical company’s domestic net sales grew by 8% to ₹4,377 million, while total net sales increased by 6% compared to the same period last year. This performance underscores the company's strong market position in the diabetes care segment, where its insulin portfolio delivered double-digit growth for the second consecutive quarter, driving margin expansion to 27% from 24% in Q2FY25. The results reflect disciplined cost management and a favorable product mix, positioning the company for sustained value creation in the Indian healthcare market.

The Board of Directors approved the unaudited financial results on August 04, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by Price Waterhouse & Co Chartered Accountants LLP, the statutory auditors, who issued a limited review report confirming compliance with applicable accounting standards under Ind AS. The Board also reconstituted the Stakeholders Relationship Committee and the Risk Management Committee effective October 01, 2026.

Key Financial Metrics

Profit before tax as a percentage of net sales improved to 27% in Q2FY26, up from 24% in Q2FY25. This margin expansion was driven by a favorable product mix and disciplined cost management. Operating expenses, comprising employee costs and other expenses, declined by 5% compared to the second quarter of 2025.

Segment Performance

The insulin portfolio continued its strong trajectory, delivering 14% growth. Sanofi maintains a leadership position in the basal analog market with a 58% value market share and 61% volume market share. Growth was powered by key brands including Lantus®, Toujeo®, and Apidra®, alongside the successful performance of Soliqua®.

The public sector business accelerated significantly, growing by 70%. This surge was attributed to the opening of new accounts for Toujeo® and Soliqua® under the CARE Accounts initiative, strengthening the company's footprint in the diabetes injectable space. Partnership revenues in Cardiovascular, Oral anti-Diabetes, and Central Nervous System segments grew by 2%, while export sales remained broadly stable amid global headwinds.

What the Numbers Show

A notable divergence exists between operating profit growth and working capital movements. While operating expenses declined by 5%, trade receivables surged from ₹1,767 million at the end of FY25 to ₹2,321 million at the end of Q1FY26, an increase of ₹554 million. This suggests potential collection pressure or extended credit terms in the distribution channel, even as cash and cash equivalents rose to ₹3,590 million. The company generated ₹2,114 million in net cash inflow from operating activities during the half-year ended June 30, 2026, down from ₹2,910 million in the same period last year, primarily due to changes in working capital dynamics.

Corporate Governance Updates

The Board also reconstituted two key committees effective October 01, 2026:

• Stakeholders Relationship Committee: Chaired by Independent Director Siraj Chaudhry, with Managing Director Deepak Arora and Whole Time Director Sudipta Chakraborty as members.
• Risk Management Committee: Chaired by Independent Director Rajani Kesari, with members Siraj Chaudhry, Deepak Arora, and Whole Time Director Mahadev Gawade.

Additionally, Rachid Ayari will step down as Whole Time Director and Chief Financial Officer on September 30, 2026. His name will be removed from the list of Key Managerial Personnel authorized to make disclosures to stock exchanges.